Literature DB >> 6889509

Concentration of endogenous oestradiol as related to oestradiol receptor sites in breast tumor cytosol.

T Thorsen, M Tangen, K F Støa.   

Abstract

Biopsies or mastectomy specimens from 69 malignant and 17 non-malignant human breast tumours have been examined with respect to cytoplasmic oestradiol receptors and endogenous oestradiol concentration. Of the malignant tumours, 45 (65%) had significant oestradiol receptor concentrations (136.7 fmol/mg protein +/- 38.3 S.E.M.). Oestradiol values in the cytosol were not correlated to receptor levels. Cytosol oestradiol concentrations in the receptor-negative tumours were normally distributed about a mean value of 7.4 fmol/mg protein +/- 0.9 (S.E.M.). Oestradiol levels were similar to the median concentration of receptor found in tumours from younger women, and consequently may influence receptor measurements in such tumours. In receptor-positive cytosols a much wider range (less than 1 to 69.7 fmol/mg protein) and a non-symmetrical distribution of oestradiol values were found which closely corresponded to the range of occupied receptor concentrations previously measured in tumour cytosol. When tumours having undetectable oestradiol values were excluded, receptor-positive cytosols had significantly higher oestradiol concentrations than those found in receptor-negative tumours (P less than 0.01). No significant difference in cytosol oestradiol concentration was found in receptor-positive and negative pre- and postmenopausal women. This would indicate that factors other than plasma levels influence tissue availability of oestradiol.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6889509     DOI: 10.1016/0277-5379(82)90002-5

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  8 in total

1.  Influence of endocrine status on biochemical and immunocytochemical estrogen and progesterone receptor assays in breast cancer patients.

Authors:  H J Helin; J J Isola; M J Helle; H Adlercreutz
Journal:  Breast Cancer Res Treat       Date:  1988-09       Impact factor: 4.872

Review 2.  Comprehensive pharmacology and clinical efficacy of aromatase inhibitors.

Authors:  V C Njar; A M Brodie
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

3.  Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer.

Authors:  James J Dignam; Kelly Wieand; Karen A Johnson; Bernard Fisher; Lei Xu; Eleftherios P Mamounas
Journal:  J Natl Cancer Inst       Date:  2003-10-01       Impact factor: 13.506

4.  Estrogen receptor status of breast cancer in Ontario.

Authors:  G E McKeown-Eyssen; I Rogers-Melamed; E A Clarke
Journal:  CMAJ       Date:  1985-11-15       Impact factor: 8.262

5.  Development of a high sensitivity, nested Q-PCR assay for mouse and human aromatase.

Authors:  Gui-Jian Liu; Giujian Liu; Yu-Sheen Wu; David Brenin; Wei Yue; Sarah Aiyar; Anne Gompel; Ji-Ping Wang; Rajeshwar Rao Tekmal; Richard J Santen
Journal:  Breast Cancer Res Treat       Date:  2007-11-02       Impact factor: 4.872

Review 6.  The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer.

Authors:  Angela Brodie; Vincent Njar; Luciana Furtado Macedo; T Sean Vasaitis; Gauri Sabnis
Journal:  Urol Oncol       Date:  2009 Jan-Feb       Impact factor: 3.498

7.  Plasma oestrogens and oestrogen receptors in breast cancer patients.

Authors:  R C Mason; W R Miller; R A Hawkins
Journal:  Br J Cancer       Date:  1985-11       Impact factor: 7.640

8.  Oestrone sulphatase activity in mammary tumours and the liver of N-nitrosomethylurea treated rats.

Authors:  T R Evans; S K Chander; M G Rowlands; R C Coombes
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.